Evidence map›Paper›PMID 38842657›Full record

ArticleInvestigational new drugs2024

Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).

Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa, Kazuyoshi Nakamura, Michihisa Moriguchi, Shunji Watanabe, Masafumi Ikeda, Hidekatsu Kuroda and 24 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. [Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Kazufumi KobayashiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sadahisa OgasawaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. ogasawaras@chiba-u.jp.
Ei ItobayashiDepartment of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Tomomi OkuboDivision of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Norio ItokawaDivision of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Kazuyoshi NakamuraDepartment of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
Michihisa MoriguchiDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shunji WatanabeDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hidekatsu KurodaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Yahaba, Japan.
Tomokazu KawaokaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
Atsushi HiraokaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Yutaka YasuiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan.
Teiji KuzuyaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan.
Rui SatoDivision of Interventional Radiology, Shizuoka Cancer Center, Nagaizumi, Japan.
Hiroaki KanzakiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keisuke KorokiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masanori InoueDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masato NakamuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Soichiro KiyonoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naoya KanogawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayuki KondoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shingo NakamotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yoshihito OzawaBiostatistics Section, Clinical Research Center, Chiba University, Chiba, Japan.
Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan.
Masanori AtsukawaDivision of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Hiroshi AikataDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
Takeshi AramakiDivision of Interventional Radiology, Shizuoka Cancer Center, Nagaizumi, Japan.
Shiro OkaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
Naoki MorimotoDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan.
Yoshito ItohDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This was an open-label, nonrandomized, multicenter, prospective study conducted at 13 institutions in Japan (jRCTs031190236). The study included Child-Pugh Class A patients with advanced HCC who had received pretreatment with atezolizumab plus bevacizumab (Atez/Bev) or lenvatinib. Ramucirumab was introduced as a second-line treatment after Atez/Bev or lenvatinib and as a third-line treatment after Atez/Bev and lenvatinib. Between May 2020 and July 2022, we enrolled 19 patients, including 17 who received ramucirumab. Additionally, seven patients received lenvatinib, another seven patients received Atez/Bev, and three patients received Atez/Bev followed by lenvatinib as prior treatment. The primary endpoint was a 6-month progression-free survival (PFS) rate, which was 14.3%. The median PFS and overall survival were 3.7 and 12.0 months, respectively. The most common grade ≥ 3 adverse events (AEs) were hypertension (23.5%), proteinuria (17.6%), and neutropenia (11.8%). The discontinuation rate due to AEs was 29.4%. Six patients progressed from Child-Pugh A to B after treatment with ramucirumab. Thirteen patients were eligible for post-ramucirumab treatment, including systemic therapy. Despite the limited number of patients, the efficacy of ramucirumab was comparable to that observed in the REACH-2 study when used after lenvatinib and Atez/Bev. However, the incidence of AEs was higher than that in the REACH-2 study.

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, HepatocellularLiver NeoplasmsRamucirumabAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabEast Asian PeopleFemaleHumansJapanMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumablenvatinibPhenylurea CompoundsQuinolinesRamucirumabHepatocellular carcinomaRamucirumabREACH-2 trialReal-world data

Identifiers

PMID38842657
PMCPMC11327193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.